Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

Abstract The efficacy and safety of sitagliptin as monotherapy were evaluated in Chinese, Indian, and Korean patients with type 2 diabetes inadequately controlled by diet and exercise. In a randomized, placebo-controlled, double-blind, 18-week trial, 530 patients with HbA1c ≥7.5% and ≤11.0% (mean ba...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2009-01, Vol.83 (1), p.106-116
Main Authors: Mohan, Viswanathan, Yang, Wenying, Son, Ho-Young, Xu, Lei, Noble, Liliane, Langdon, Ronald B, Amatruda, John M, Stein, Peter P, Kaufman, Keith D
Format: Article
Language:English
Subjects:
Adult
Aged
China
Diabetes Mellitus, Type 2 - drug therapy
Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
DPP-4 inhibitor
Endocrinology & Metabolism
Female
Glycemic control
Humans
Hypoglycemic Agents - therapeutic use
Incretins
India
Korea
Male
Middle Aged
Pyrazines - therapeutic use
Sitagliptin
Sitagliptin Phosphate
Triazoles - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The efficacy and safety of sitagliptin as monotherapy were evaluated in Chinese, Indian, and Korean patients with type 2 diabetes inadequately controlled by diet and exercise. In a randomized, placebo-controlled, double-blind, 18-week trial, 530 patients with HbA1c ≥7.5% and ≤11.0% (mean baseline 8.7%) received sitagliptin 100 mg once daily or placebo. Compared with placebo, sitagliptin significantly ( p < 0.001) reduced mean HbA1c (−1.0%), fasting plasma glucose (−1.7 mmol/L), and 2-h postprandial glucose (−3.1 mmol/L), and a significantly (p < 0.001) greater proportion of sitagliptin-treated versus placebo-treated patients achieved HbA1c
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2008.10.009